EGFR and neoplasm: One of the best-established mechanisms is the development of mutations in the EGFR extracellular domain (ECD), occurring in approximately 20% of CRCs following EGFR blockade, which interfere with antibody binding, leading to tumor relapse [13,14,15,16,17].